Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that treating asymptomatic or mild COVID-19 with cepharanthine did not significantly reduce the time to a negative test result, though 60 mg/day showed a non-significant trend needing further validation.

In this study, 60 mg/day of Cepharanthine significantly reduced the time to a negative COVID-19 test among de novo infected patients with good compliance, though 120 mg/day showed no such effect.

This study suggests that combining topical squaric acid dibutylester with other therapies may improve hair regrowth in patients with alopecia areata unresponsive to topical therapy alone.

This review discusses the antiviral potential of cepharanthine against SARS-CoV-2, noting its effectiveness in preclinical models but presenting no new clinical results.

This study found that pulmonary delivery of cepharanthine significantly improved bioavailability and may provide protective effects against pulmonary fibrosis related to COVID-19 infection in a rat model.

This review highlights cepharanthine as a promising candidate for COVID-19 treatment due to its antiviral activity against SARS-CoV-2 and favorable pharmacokinetic and safety profile, but reports no new clinical results.

This study found that cepharanthine may be a promising treatment for enterovirus infections, as it offered full protection to mice against lethal EV71 challenges and reduced viral titers and pathology.

This case study reports a patient with post-COVID-19 diffuse alopecia who experienced gradual hair recovery to near pre-infection levels within seven months.

In this study, male participants with early androgenetic alopecia experienced a significant increase in hair growth rate after applying topical lipoid cepharanthine lotion for six months.

This review discusses the historical development, mechanisms of action, and potential new clinical applications of the drug cepharanthine, highlighting its multi-faceted pharmacological properties; it reports no new clinical results.

This study found that topical cepharanthine increased IGF-I production in human dermal papilla cells, suggesting it may stimulate hair growth and be a promising treatment option for androgenetic alopecia.

This review reports that the compound Cepharanthine shows promise as a cancer therapy by inducing cell death, arresting cell growth, inhibiting tumor progression, modulating key oncogenic pathways, and reversing multidrug resistance, suggesting its potential for further investigation in oncology.

In this study, researchers developed a biomimetic anti-inflammatory nanosystem (MM-CEP/NLCs) that significantly reduced the severity of acute lung injury in vivo by targeting and accumulating in lung inflammation sites, showcasing its potential for treating inflammation.

This article reviews current guidelines for managing androgenetic alopecia and highlights the need for guidelines tailored to Japan; it reports no new clinical results.

In this study, dry powder inhalers containing Cepharanthine were administered to rats with acute lung injury, significantly reducing pulmonary edema, hemorrhage, and inflammatory markers, suggesting its potential as an effective anti-inflammatory treatment when inhaled directly into the lungs.

The researchers reviewed cepharanthine, a long-used bisbenzylisoquinoline alkaloid, for its antiviral properties, including significant inhibition of SARS-CoV-2. They discussed cepharanthine's other pharmacological actions, highlighted plasma membrane fluidity as a key antiviral mechanism, and examined its safety, bioavailability, and potential for new clinical applications.

This study found that erythrocyte-anchored CPA-encapsulated nanoparticles improved the delivery and accumulation of Cepharanthine in the lungs, enhancing its effectiveness in treating acute lung injury by reducing inflammatory responses.

This study suggests that cepharanthine may play an important role in treating SARS-CoV-2 infection by targeting multiple pathways and related targets associated with COVID-19.

This case study describes a rare instance of alopecia universalis in a Japanese patient following an mRNA COVID-19 vaccination.

This study found that the natural alkaloid cepharanthine effectively inhibited porcine epidemic diarrhea virus infection in newborn piglets.

This study explored new molecular structures as potential COVID-19 treatments, identifying a compound called Hit15 that inhibited viral infection in lab settings and reduced inflammation markers in human neutrophils, suggesting further development is warranted.

This review highlights phytochemicals, particularly flavonoids and phenolics, as potential supportive treatments for SARS-CoV-2 by interfering with viral proteins and providing anti-inflammatory effects; it suggests a foundation for future therapeutic and vaccine development efforts.

This review paper discusses the effectiveness of repurposed drugs and potential novel therapies for treating COVID-19, highlighting remdesivir as the only FDA-approved medication and listing others with Emergency Use Authorization.

This review discusses various amino acid-derived plant defensive compounds and highlights their potential as drug leads due to their potent antimicrobial properties, but reports no new experimental results.

This study concluded that Metformin may be suitable for prophylaxis or mild COVID-19, while a combination of Oseltamivir, Tamoxifen, and Dexamethasone could benefit moderate to severe cases, highlighting the need for more trials on other drug candidates.

This study found that orally administered Annurca apple extract improved hair length, thickness, weight, and density in mice, while also increasing the expression of hair growth-related genes and proteins, suggesting potential as a natural treatment for hair loss.

This study found that procyanidin oligomers, particularly dimers and trimers, significantly promoted hair growth in mice and hair epithelial cell cultures, suggesting potential use as hair growth agents.

In this study, the researchers observed that a new hair serum containing NX35growthTM molecules increased hair density, volume, and thickness in all hair types among 51 participants, following regular daily application over 56 days.

This study found that dermoscopic indicators like black dots and tapering hairs are valuable markers for diagnosing and assessing the severity and activity of alopecia areata in Asian patients.

This review examines topical immunotherapy for severe alopecia areata, noting that diphencyprone and squaric acid dibutylester are non-mutagenic options with similar efficacy but different practical considerations, and reports no new clinical results.